Joint Ventures and Other Equity Method Affiliates (Tables)

12 Months Ended

Dec. 31, 2012

Equity Income from Affiliates

Equity income from affiliates reflects the performance of the Company’s joint ventures and other equity method affiliates and was comprised of the following:

Years Ended December 31	2012		2011		2010
AstraZeneca LP	$	621	$	574	$	546
Other (1)		21		36		41
	$	642	$	610	$	587

(1) Primarily reflects results from Sanofi Pasteur MSD and Johnson & Johnson°Merck Consumer Pharmaceuticals Company (which was disposed of on September 29, 2011).

Summarized Financial Information for AZLP

Summarized financial information for AZLP is as follows:

Years Ended December 31	2012		2011		2010
Sales	$	4,694	$	4,659	$	4,991
Materials and production costs		2,177		2,023		2,568
Other expense, net		1,312		1,392		886
Income before taxes (1)		1,205		1,244		1,537
December 31	2012		2011
Current assets	$	3,662	$	4,251
Noncurrent assets		206		250
Current liabilities		3,145		3,915

⁽¹⁾  Merck’s partnership returns from AZLP are generally contractually determined as noted above and are not based on a percentage of income from AZLP, other than with respect to Merck’s 1% limited partnership interest.

Summarized Financial Information for Affiliates (Excluding AZLP)

Summarized information for those affiliates (excluding AZLP disclosed separately above) is as follows:

Years Ended December 31	2012		2011 (1)		2010
Sales	$	1,295	$	1,331	$	1,486
Materials and production costs		573		584		598
Other expense, net		705		642		776
Income before taxes		17		105		112
December 31	2012		2011
Current assets	$	971	$	614
Noncurrent assets		112		75
Current liabilities		480		478
Noncurrent liabilities		97		140

⁽¹⁾ Includes information for the JJMCP joint venture until its divestiture on September 29, 2011.